Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Veterinary Vaccine (ASF)
- Development stage
- Preclinical
- Lead developer
- Quratis
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Veterinary Vaccine (ASF) is a preclinical-stage veterinary vaccine being developed by Quratis, a biopharmaceutical company, targeting African Swine Fever (ASF) — a highly contagious and lethal hemorrhagic disease affecting domestic pigs and wild boar caused by the African Swine Fever Virus (ASFV). The vaccine is designed to elicit an immune response against ASFV in swine. Specific details such as the active ingredient, brand name, precise biological target, and vaccine platform are not publicly disclosed, consistent with its early preclinical development stage.
- Other names
- ASF veterinary vaccineAfrican Swine Fever veterinary vaccine
Beyond the preview
Go deeper on Veterinary Vaccine (ASF).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Veterinary Vaccine (ASF).